Education and Training
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: RMC-6291
Eligibility
Inclusion Criteria:
- Subject must be ≥18 years of age.
- Subject must have pathologically documented, locally advanced or metastatic
KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has
previously been treated with standard-of-care therapies for respective tumor types, is
intolerant to, or is considered ineligible for standard-of-care anticancer treatments.
- ECOG performance status 0 or 1
- Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation
- Adequate organ function
Exclusion Criteria:
- Primary central nervous system (CNS) tumors
- Active brain metastases
- Known impairment of GI function that would alter the absorption
- Major surgical procedures within 28 days or non-study-related minor procedures within
7 days of treatment.
- Prior therapy with KRASG12C (ON) inhibitor
Other inclusion/exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Feriel Buchholz
650-721-4090
I'm interested